TY - JOUR
T1 - Pancreatic Ductal Adenocarcinoma, β-blockers, and Antihistamines
T2 - A Clinical Trial Is Needed
AU - Baker, Jillian G.
AU - Sloan, Erica K.
AU - Pfleger, Kevin D.G.
AU - McCormick, Peter J.
AU - Salmerón, Cristina
AU - Insel, Paul A.
PY - 2025
Y1 - 2025
N2 - Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers. Globally, each year, almost half a million people die from pancreatic cancer.1 PDAC has the lowest 5-year survival of all major cancers (2%-12%2,3 https://cancerstatisticscenter.cancer.org, Figure 1) and is predicted to become the second highest cause of cancer deaths in this decade3,4 (Figure 2). Approximately 15% of patients with PDAC are diagnosed early and can be treated with surgery and adjuvant chemotherapy; yet their 5-year survival is only 20%-27%.3 Most PDAC patients are diagnosed after the cancer has spread beyond the pancreas and have very limited survival: 6-11 months for advanced local PDAC and 2-6 months for metastatic disease.3 Overall survival from the time of diagnosis is 5-6 months.2,3,5 Therapeutic approaches, such as immunotherapy and targeted therapies, have improved survival of other cancers but have not had a major impact on the survival of PDAC patients.
AB - Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers. Globally, each year, almost half a million people die from pancreatic cancer.1 PDAC has the lowest 5-year survival of all major cancers (2%-12%2,3 https://cancerstatisticscenter.cancer.org, Figure 1) and is predicted to become the second highest cause of cancer deaths in this decade3,4 (Figure 2). Approximately 15% of patients with PDAC are diagnosed early and can be treated with surgery and adjuvant chemotherapy; yet their 5-year survival is only 20%-27%.3 Most PDAC patients are diagnosed after the cancer has spread beyond the pancreas and have very limited survival: 6-11 months for advanced local PDAC and 2-6 months for metastatic disease.3 Overall survival from the time of diagnosis is 5-6 months.2,3,5 Therapeutic approaches, such as immunotherapy and targeted therapies, have improved survival of other cancers but have not had a major impact on the survival of PDAC patients.
UR - http://www.scopus.com/inward/record.url?scp=85217915014&partnerID=8YFLogxK
U2 - 10.1093/function/zqae050
DO - 10.1093/function/zqae050
M3 - Comment / Debate
C2 - 39547938
AN - SCOPUS:85217915014
SN - 2633-8823
VL - 6
JO - Function
JF - Function
IS - 1
M1 - zqae050
ER -
